Order Article Reprints

Abou Assi L, Alkhansa S, Njeim R, Ismail J, Madi M, Ghadieh HE, Al Moussawi S, Azar TS, Ayoub M, Azar WS, et al. Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition. Pharmaceutics. 2024; 16(7):955. https://doi.org/10.3390/pharmaceutics16070955

Abou Assi, Layal, Sahar Alkhansa, Rachel Njeim, Jaafar Ismail, Mikel Madi, Hilda E. Ghadieh, Sarah Al Moussawi, Tanya S. Azar, Maurice Ayoub, William S. Azar, and et al. 2024. "Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition" Pharmaceutics 16, no. 7: 955. https://doi.org/10.3390/pharmaceutics16070955

Abou Assi, L., Alkhansa, S., Njeim, R., Ismail, J., Madi, M., Ghadieh, H. E., Al Moussawi, S., Azar, T. S., Ayoub, M., Azar, W. S., Hamade, S., Nawfal, R., Haddad, N.-R., Harb, F., Faour, W., Khalil, M. I., & Eid, A. A. (2024). Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition. Pharmaceutics, 16(7), 955. https://doi.org/10.3390/pharmaceutics16070955